公司目前将对富特科技的股权投资指定为以公允价值计量且其变动计入其 他综合收益的金融资产。除来自富特科技的分红（若有）计入投资收益外，其 公允价值变动将不会产生投资收益，不影响净利润，但会影响归属于上市公司 股东的所有者权益。公司将继续履行信息披露义务，请投资者注意投资风险。 宏达高科控股股份有限公司 关于参股公司股票上市交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司参股的浙江富特科技股份有限公司（下称"富特科技"）人民币普通 股股票已于 2024 年 9 月 4 日在深圳证券交易所上市，证券简称为"富特科技", 证券代码为"301607.SZ"。富特科技目前人民币普通股股份总数为 111,014,571 股，其中 22,368,152 股股票自上市之日起开始上市交易。 公司于 2020 年 10 月公告拟对富特科技进行增资参股，并于同年 12 月完 成入股（详见公司公告 2020-043、2024-045、2020-047）。截至本公告披露日， 公司持有富特科技首次公开发行前股份 3,050,626 股，持股比例为 2.7479%，该 部分 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 275,300,244.25, representing a 10.46% increase compared to CNY 249,239,367.47 in the same period last year[24]. - The net profit attributable to shareholders of the listed company decreased by 12.41% to CNY 42,364,686.99 from CNY 48,364,692.69 year-on-year[24]. - The basic earnings per share decreased by 11.11% to CNY 0.24 from CNY 0.27 in the same period last year[24]. - The company achieved operating revenue of CNY 275.30 million in the first half of 2024, representing a year-on-year increase of 10.46%[36]. - The net profit attributable to shareholders of the listed company was CNY 42.36 million, a decrease of 12.41% year-on-year, while the net profit of the parent company increased by 13.21% to CNY 52.88 million[36]. - The company's main business revenue from fabric weaving reached CNY 192.12 million, up 12.79% year-on-year, contributing to stable growth in revenue and profit[37]. - The total revenue for the first half of 2024 reached CNY 184,282,555.89, representing a year-on-year increase of 11.88%[42]. - The gross profit margin for the fabric weaving segment was 29.07%, with a revenue increase of 11.88% compared to the previous year[43]. - The medical device segment reported a revenue of CNY 26,372,029.78, with a gross profit margin of 52.20%, although revenue decreased by 18.48% year-on-year[43]. - The total comprehensive income for the first half of 2024 was ¥14,676,780.99, significantly lower than ¥51,203,963.69 in the previous year, reflecting a decrease of 71.3%[144]. Cash Flow and Liquidity - The net cash flow from operating activities dropped significantly by 55.49% to CNY 14,723,864.33, compared to CNY 33,081,691.19 in the previous year[24]. - The company reported a significant decrease in cash and cash equivalents, indicating potential liquidity challenges[152]. - The company's cash and cash equivalents decreased to ¥207,892,280.20 from ¥536,148,860.18, representing a decline of approximately 61.3%[134]. - The ending balance of cash and cash equivalents was ¥176,337,886.30, down from ¥342,672,815.75 in the previous period[152]. - Cash flow from operating activities generated a net amount of ¥14,723,864.33, down 55.54% from ¥33,081,691.19 in the same period last year[148]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,159,025,739.65, a decrease of 0.52% from CNY 2,170,375,592.53 at the end of the previous year[24]. - The net assets attributable to shareholders of the listed company decreased by 0.60% to CNY 1,983,991,327.83 from CNY 1,995,956,420.04 at the end of the previous year[24]. - Cash and cash equivalents decreased by 15.07% to ¥207,892,280.20, accounting for 9.63% of total assets[53]. - Accounts receivable increased to ¥139,019,673.87, representing 6.44% of total assets, up from 5.31%[53]. - Total liabilities decreased to ¥123,746,919.30 from ¥137,186,762.36, reflecting a reduction of approximately 9.8%[143]. Research and Development - Research and development expenses increased by 5.48% to CNY 14.10 million, reflecting the company's commitment to innovation[38]. - The company has allocated 1.2 billion yuan for research and development in new technologies and products for the current fiscal year[159]. - Research and development expenses increased to ¥14,100,485.95, compared to ¥13,367,490.43, representing a growth of 5.5%[143]. Market and Industry Risks - The company is exposed to risks related to macroeconomic conditions, downstream market conditions, raw material and product prices, and product quality in the textile industry[5]. - The medical device sector faces increasing competition from multinational companies and domestic enterprises, particularly in the ultrasound diagnostic equipment market[67]. - The company is exposed to raw material price volatility, particularly for nylon, polyester, and various dyes, which could impact production costs[68]. - The international market presents risks due to rising trade protectionism and currency fluctuations, affecting export growth in the knitting and medical device industries[68]. Shareholder Information - The total number of restricted shares increased from 38,862,923 (21.99%) to 40,083,514 (22.68%) due to the addition of 1,220,591 shares[115]. - Chairman Shen Guofu increased his shareholding by 1,305,700 shares, bringing his total to 42,600,090 shares, which is 24.10% of the total shares[115]. - The total number of shareholders at the end of the reporting period was 16,086[120]. Environmental Compliance - The company complies with environmental regulations and has established standards for pollutant emissions, with no reported exceedances in wastewater discharge limits[79]. - The company has a wastewater treatment capacity of 8,000 tons per day, with 4,000 tons discharged and 4,000 tons reused[80]. - The total greenhouse gas emissions for the first half of 2024 amounted to 17,965 tons of CO2, with emissions from fuel combustion at 1,643 tons, purchased electricity at 4,805 tons, and heat generation at 11,517 tons[84]. Corporate Governance - The company has not engaged in any major acquisitions or mergers during the reporting period[97]. - There were no major lawsuits or arbitration matters reported during the period[94]. - The half-year financial report has not been audited[92]. Strategic Outlook - The company plans to expand its market presence through new product launches and technological advancements in the upcoming quarters[159]. - The company aims to achieve a revenue growth target of 10% for the next fiscal year, driven by market expansion and new product offerings[159]. - The company is exploring potential mergers and acquisitions to enhance its market position and product portfolio[159].

证券代码：002144 股票简称：宏达高科 公告编号：2024-024 宏达高科控股股份有限公司 关于公司完成工商变更登记并取得营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 宏达高科控股股份有限公司（以下简称"公司"）分别于2024年4月24日 召开第七届董事会第二十一次会议，2024年5月28日召开2023年年度股东大会， 审议通过了《关于变更公司注册地址并修订<公司章程>的议案》。公司注 册地址由"浙江省海宁市许村镇建设路118号"变更为"浙江省海宁市许村镇大 桥路275号"。具体内容详见公司刊登于巨潮资讯网上（www.cninfo.com.cn） 的相关公告。 一、公司营业执照变更情况 近日，公司已完成了工商变更登记手续，取得了浙江省市场监督管理局 核发的《营业执照》，变更后的企业登记信息如下： 1、名称：宏达高科控股股份有限公司 8、经营范围： 投资管理，资产管理咨询服务，针织及纺织面料、服装、 合成革的制造、加工、销售；印染；房屋租赁，化纤丝、染化料(不含危险品) 的销售。经营进出口业务(详见《进出口企业资格证书》)。(依法须经批准 ...

2023年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 证券代码：002144 股票简称：宏达高科 公告编号：2024-023 宏达高科控股股份有限公司 一、股东大会审议通过权益分派方案情况 1、宏达高科控股股份有限公司(以下简称"公司")2023年年度权益分派 方案已获2024年5月28日召开的公司2023年年度股东大会审议通过，股东大 会决议公告已于2024年5月29日刊登在巨潮资讯网（www.cninfo.com.cn）和 《证券时报》。 2、自权益分派方案披露至实施期间公司股本总额未发生变化。 3、本次实施的权益分派方案与股东大会审议通过的权益分派方案一 致。 4、本次实施权益分派方案距离股东大会审议通过的时间未超过两个 月。 5、本次权益分派方案按固定总额的方式分配，以公司现有总股本 176,762,528股为基数，向全体股东每10股派1.50元人民币现金（含税），分 派总金额为26,514,379.20元。 二、权益分派方案 本公司2023年年度权益分派方案为：以公司现有总股本176,762,528股为 基数，向全体股东每1 ...

宏达高科控股股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更前次股东大会决议。 一、会议召开和出席情况 1、宏达高科控股股份有限公司（以下简称"公司"）2023 年年度股东大会于 2024 年 5 月 28 日在浙江省海宁市许村镇大桥路 275 号公司会议室召开。本次会 议由公司董事会召集，由公司董事长沈国甫先生主持。本次会议的召集、召开与 表决程序符合《公司法》、《上市公司股东大会规则》等有关法律、法规、规范性 文件和《公司章程》的规定。 证券代码：002144 股票简称：宏达高科 公告编号：2024-019 2、参加本次股东大会现场会议和网络投票的股东及股东代表共 11 人，代表 的股份总数为 61,841,764 股，占公司有表决权股份总数的 34.99%。其中参与表 决的中小股东及股东代表共计 6 人，代表的股份总数为 8,754,025 股，占公司有 表决权股份总数的 4.95%。 3、为尊重中小投资者利益，提高中小投资者对公 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 宏达高科控股股份有限公司（以下简称"公司"）于 2024 年 5 月 28 日召开了 2023 年年度股东大会，选举产生了公司第八届董事会。同日下午三点半，公司董事 会在浙江省海宁市许村镇大桥路 275 号公司会议室以现场方式召开了第八届董事会 第一次会议。 本次会议由公司董事沈国甫先生主持，应到董事 9 位，实到董事 9 位，公司监 事、高级管理人员列席了本次会议，会议的召开符合法律、法规、规章及《公司章 程》的规定。 与会董事认真审议，以现场与通讯相结合的表决的方式，作出了如下决议： 1、以 9 票同意、0 票反对、0 票弃权的表决结果审议通过了《关于选举公司第 八届董事会董事长的议案》。 本次董事会选举沈国甫先生为第八届董事会董事长，任期与第八届董事会一致， 即自 2024 年 5 月 28 日至 2027 年 5 月 27 日。 证券代码：002144 股票简称：宏达高科 公告编号：2024-020 宏达高科控股股份有限公司 第八届董事会第一次会议决议公告 2、以 9 票同意、0 票反对、0 票弃权的表决 ...

证券代码：002144 股票简称：宏达高科 公告编号：2024-022 以上人员任期自本次董事会审议通过之日起至本届董事会进行换届选举之 日止。以上人员简历详见同日披露于证券时报和巨潮资讯网的《第八届董事会第 一次会议决议的公告》。公司董事会审计委员会就公司聘任财务总监和内审 机构负责人的事项进行事前审议，并做出了同意的意见。 | 姓名 | 马强强 | 沈婷婷 | | --- | --- | --- | | 联系地址 | 浙江省海宁市许村镇大桥路 275 号 | 浙江省海宁市许村镇大桥路 275 号 | | 电话 | 0573-87550882 | 0573-87566909 | | 传真 | 0573-87552681 | 0573-87552681 | | 电子信箱 | mqq@zjhongda.com.cn | stt@zjhongda.com.cn | 马强强先生和沈婷婷女士联系方式如下： 特此公告。 宏达高科控股股份有限公司 关于聘任公司高级管理人员、证券事务代表、内审机构负 责人的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为完善公司治理 ...

证券代码：002144 股票简称：宏达高科 公告编号：2024-021 1、以 3 票同意、0 票反对、0 票弃权的表决结果审议通过了《关于选举第八 届监事会主席的议案》。 与会监事经认真审议，一致同意选举陆维敏先生（简历详见附件）为公司第 八届监事会主席，任期与第八届监事会一致，即自 2024 年 5 月 28 日至 2027 年 5 月 27 日。 备查文件：第八届监事会第一次会议决议。 宏达高科控股股份有限公司 第八届监事会第一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宏达高科控股股份有限公司（以下简称"公司"）于 2024 年 5 月 28 日召开 了 2023 年年度股东大会，审议通过了《选举股东代表监事的议案》，选举了陆维 敏先生、许铨先生为公司监事，他们与 2024 年 5 月 15 日召开的 2024 年第一次 职工代表大会选举产生的职工代表监事周美玲女士一起组成了公司第八届监事 会。同日，在海宁市许村镇大桥路 275 号公司会议室召开了第八届监事会第一次 会议。 本次会议由监事陆维敏先生主持，应到监事 3 位，实到监事 ...

北京德恒律师事务所 关于宏达高科控股股份有限公司 二〇二三年年度股东大会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于宏达高科控股股份有限公司二〇二三年度股东大会的法律意见 北京德恒律师事务所 关于宏达高科控股股份有限公司 二〇二三年年度股东大会的 法律意见 编号：01G20240435 致：宏达高科控股股份有限公司 北京德恒律师事务所受宏达高科控股股份有限公司（下称"公司"或"宏达 高科"）委托，指派马恺律师、徐晓璇律师（下称"本所律师"）列席公司于 2024 年 5 月 28 日 14:00 召开的二〇二三年年度股东大会（下称"本次股东大会"）， 对本次股东大会进行见证，并出具法律意见。 本法律意见根据《中华人民共和国公司法》（下称"《公司法》"）、《中 华人民共和国证券法》（下称"《证券法》"）、《上市公司股东大会规则》（下 称"《股东大会规则》"）等有关法律、法规和规范性文件以及《宏达高科控股 股份有限公司章程》（下称"《公司章程》"）和《宏达高科控股股份有限公司 股东大 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 120,997,467.59, representing a 0.70% increase compared to CNY 120,153,487.21 in the same period last year[5]. - Net profit attributable to shareholders was CNY 17,877,888.35, up 3.80% from CNY 17,223,917.74 year-on-year[5]. - The company's net profit for Q1 2024 was CNY 18,056,268.14, an increase from CNY 17,522,185.87 in Q1 2023, representing a growth of approximately 3.06%[18]. - Operating revenue for Q1 2024 was CNY 134,889,551.28, compared to CNY 131,195,516.79 in Q1 2023, indicating a year-over-year increase of about 2.06%[21]. - The total operating profit for Q1 2024 was CNY 20,554,810.76, compared to CNY 19,705,509.83 in Q1 2023, marking an increase of approximately 4.31%[18]. - The total comprehensive income for Q1 2024 was CNY 6,724,068.14, compared to CNY 19,325,035.87 in Q1 2023, indicating a significant decrease[19]. Cash Flow and Assets - The net cash flow from operating activities increased by 15.02% to CNY 19,135,862.21 from CNY 16,636,610.36 in the previous year[5]. - Cash and cash equivalents increased by 803.02% to CNY 123,239,403.06, primarily due to net increases from investment and financing activities[9]. - Cash and cash equivalents increased to RMB 657,844,131.12 from RMB 536,148,860.18, representing a growth of 22.67%[14]. - The cash and cash equivalents at the end of Q1 2024 amounted to CNY 657,803,156.18, an increase from CNY 512,266,644.24 at the end of Q1 2023, representing a growth of approximately 28.38%[22]. - Total assets as of March 31, 2024, were CNY 2,228,108,415.79, a 2.66% increase from CNY 2,170,375,592.53 at the end of the previous year[5]. - Total current assets rose to RMB 916,204,064.93, up 9.34% from RMB 838,089,609.64 at the beginning of the period[15]. - Total assets increased to RMB 2,228,108,415.79 from RMB 2,170,375,592.53, reflecting a growth of 2.65%[16]. Liabilities and Shareholder Information - Total liabilities increased to RMB 220,487,529.96 from RMB 169,478,774.84, an increase of 30.06%[16]. - The number of ordinary shareholders at the end of the reporting period was 17,473, with the largest shareholder holding 24.10% of the shares[10]. - The company's major shareholder, Mr. Shen Guofu, increased his stake by acquiring 1,305,700 shares, bringing his total ownership to 42,600,090 shares, or 24.10% of the total share capital[12]. - Short-term borrowings surged by 725.52% to CNY 83,590,847.81, attributed to new low-interest bank loans[9]. Expenses and Financial Costs - Total operating costs decreased to RMB 104,055,545.06, down 2.58% from RMB 106,830,552.14 in the previous year[17]. - The company experienced a 139.25% increase in financial expenses, mainly due to increased foreign exchange gains[9]. - The company's tax expenses for Q1 2024 were CNY 2,514,074.23, up from CNY 2,133,700.40 in Q1 2023, reflecting an increase of about 17.80%[18]. - The company reported a financial expense of CNY -2,320,733.43 in Q1 2024, compared to CNY -970,017.78 in Q1 2023, reflecting a worsening in financial costs[18]. Investments and R&D - The company holds a long-term equity investment of RMB 430,578,066.76, slightly up from RMB 428,401,115.84[15]. - Research and development expenses for Q1 2024 were CNY 6,664,605.96, slightly higher than CNY 6,559,933.54 in Q1 2023, showing an increase of about 1.60%[18]. - The company achieved an investment income of CNY 2,210,483.00 in Q1 2024, down from CNY 4,051,036.65 in Q1 2023, indicating a decline of about 45.49%[18]. Government Subsidies - The company received government subsidies amounting to CNY 688,457.24, a decrease of 28.14% compared to the previous year[9]. IPO Activity - The company is involved in the initial public offering of Zhejiang Fute Technology Co., Ltd., which received approval from the China Securities Regulatory Commission[12].